Please assess the completion status of the following clinical trial:

Trial Title: A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of RA~* Subjects who have active RA at the time of screening~* Subjects who haven't used any antirheumatic drugs or have used antirheumatic drugs for more than 3 months at the time of screening~* Written informed consent~Exclusion Criteria:~* Subjects with serious cardiovascular, renal, hematologic or endocrine diseases~* Pregnant or lactating women~* ALT\>1.5×ULN, AST\>1.5×ULN, Cr\>135umol/L~* WBC\<4×109/L，HGB\<85g/L，PLT\<100×109/L~* Subjects with uncontrolled infection~* Patients with active gastrointestinal diseases (such as gastric ulcer, etc.)~* Allergic to any of the study drugs~* History of alcoholism~* Subjects receiving live vaccines within 3 months prior to study entry~* Subjects participating in other clinical study within 3 months prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iguratimod (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).